Cargando…
Three Doses of COVID-19 Vaccines: A Retrospective Study Evaluating the Safety and the Immune Response in Patients with Multiple Sclerosis
Since the beginning of the mass immunization of patients with multiple sclerosis (MS), many data on the efficacy and safety of COVID-19 vaccines have been produced. Considering that MS is an autoimmune disease and that some disease-modifying therapies (DMTs) could decrease the antibody response agai...
Autores principales: | Maniscalco, Giorgia Teresa, Di Giulio Cesare, Daniele, Liguori, Valerio, Manzo, Valentino, Prestipino, Elio, Salvatore, Simona, Di Battista, Maria Elena, Moreggia, Ornella, Ziello, Antonio Rosario, Andreone, Vincenzo, Scavone, Cristina, Capuano, Annalisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342738/ https://www.ncbi.nlm.nih.gov/pubmed/37445269 http://dx.doi.org/10.3390/jcm12134236 |
Ejemplares similares
-
Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study
por: Ziello, Antonio, et al.
Publicado: (2021) -
Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report
por: Maniscalco, Giorgia T., et al.
Publicado: (2021) -
The Safety Profile of COVID-19 Vaccines in Patients Diagnosed with Multiple Sclerosis: A Retrospective Observational Study
por: Maniscalco, Giorgia Teresa, et al.
Publicado: (2022) -
Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies
por: Maniscalco, Giorgia Teresa, et al.
Publicado: (2022) -
Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects
por: Maniscalco, Giorgia Teresa, et al.
Publicado: (2022)